Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 4/20 | 1.00 |
| ▸ | RORA | P35398 | 5/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.66 |
| ▸ | RORC | P51449 | 4/20 | 0.66 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | RORB | Q92753 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | IL1RN | P18510 | 1/20 | 0.58 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11414910 | 0.91 | NR1H3 (0.84) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL12334557 | 0.91 | NR1H3 (0.84) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL12334076 | 0.88 | RORA (0.78) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL2945324 | 0.86 | RORA (0.76) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL2942043 | 0.85 | RORA (0.74) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL11419365 | 0.85 | RORA (0.74) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL12334066 | 0.85 | RORA (1.00) | NR1H3RORANR1H2RORCNR1H4 | |
| SCHEMBL21072953 | 0.84 | NR1H3 (0.70) | NR1H3RORANR1H2RORC | |
| SCHEMBL2567685 | 0.83 | NR1H3 (0.71) | NR1H3MAPTLMNANPSR1MEN1 | |
| SCHEMBL11416348 | 0.81 | RORA (0.73) | NR1H3RORANR1H2RORCRORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4503232-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| JP-2004521113-A | — | — | 2004-07-15 | — | — | JP | claimed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
| EP-1353662-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-22 | — | — | EP | claimed |
| WO-2002058690-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | claimed |
| EP-2882710-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | Phenex Pharmaceuticals AG (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023367-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2014-02-13 | — | — | WO | disclosed |
| EP-2542537-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | Phenex Pharmaceuticals AG (DE) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107248-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| US-7229816-B2 | Sitosterolemia susceptibility gene (SSG) polypeptides | AMGEN INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| US-4230635-A | ANTIHYPERTENSIVE, HERBICIDES, FUNGICIDES | SCHERING CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | NR1H3 1227/4885RORA 2055/4885NR1H2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.